Has Aileen Chen, MD received payments from drug or device companies?

Yes. Drug and device makers reported $2,014 in general payments to Aileen Chen, MD across 7 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Aileen Chen, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Aileen Chen, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Aileen Chen, MD

Radiation Oncology · Houston, TXNPI 1801876560

Payments from drug & device makers

What this record shows

This record is dominated by grants: $1,486 of the $2,014 with a category attached, or 73.8%. Novocure Inc. accounts for 93.7% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2024 at $1,594 and has fallen 81.7% since, to $291 in 2025.

$2,014in general payments, 2019–2025

Across 7 payments — averaging $287.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novocure Inc.$2K
Elekta, Inc.$90
Gilead$19
Jazz Pharmaceuticals Inc.$18

$97,951in research payments, 2019–2025

Across 2 payments — averaging $48,976 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Novocure GmbH$98K

What the payments were for

Grants$1,48674%
Food & beverage$52826%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novocure Inc.	4	$1,887
Elekta, Inc.	1	$90
Gilead	1	$19
Jazz Pharmaceuticals Inc.	1	$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,014 in reported general payments places this provider in the 70th percentile of 418 radiation oncology providers in Texas.

See all radiation oncology providers in Texas →

Medicare billing

Part B allowed, 2024

$165,215

Medicare patients

197

Services billed

1,858

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other radiation oncology in Houston

James WelshHouston$421K
Stephen ChunHouston$344K
Chad TangHouston$183K
Phuoc TranHouston$177K
Steven LinHouston$105K
Benjamin SchrankHouston$100K
Abhilasha PatelHouston$76K
Joe ChangHouston$50K
Daniel GomezHouston$47K
David RosenthalHouston$40K

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →